These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Review: clinical trials in peptic ulcer disease--problems of methodology and interpretation. Lauritsen K; Rask-Madsen J Aliment Pharmacol Ther; 1987 Apr; 1(2):91-123. PubMed ID: 2979220 [TBL] [Abstract][Full Text] [Related]
24. Pirenzepine in peptic ulcer. Introduction to clinical trials reports. Chierichetti SM; Gaetani M; Petrin G Scand J Gastroenterol Suppl; 1979; 57():7-10. PubMed ID: 396661 [TBL] [Abstract][Full Text] [Related]
25. Present and future treatment of peptic ulcer and potential role of DE-NOL. Scand J Gastroenterol Suppl; 1982; 80():49-57. PubMed ID: 6761852 [No Abstract] [Full Text] [Related]
26. The pharmacology of peptic ulcer disease. Ippoliti A; Peterson W Clin Gastroenterol; 1979 Jan; 8(1):53-67. PubMed ID: 369747 [No Abstract] [Full Text] [Related]
27. Medical treatment of peptic ulcer disease: is it truly efficacious? Goldberg MA Am J Med; 1984 Oct; 77(4):589-91. PubMed ID: 6207724 [No Abstract] [Full Text] [Related]
28. [Prevention of stress ulcers with synthetic depot secretin]. Theisinger W; Spilker G; Bader M Med Klin; 1981 May; 76(10):291-3. PubMed ID: 7015093 [TBL] [Abstract][Full Text] [Related]
29. [Randomized double-blind placebo-controlled study of drugs with anti-ulcer action and their use in associated pathology]. Ivashkin VT; Minasian GA Ter Arkh; 1988; 60(1):78-83. PubMed ID: 3129806 [TBL] [Abstract][Full Text] [Related]
30. [Antisecretor treatment of digestive hemorrhage associated to peptic ulcer: an approximation to the available evidence]. Bustamante Baléna M; Ponce García J Rev Clin Esp; 2004 Mar; 204(3):161-8. PubMed ID: 15025985 [No Abstract] [Full Text] [Related]
31. [Tripotassium-dicitrato bismuthate in the treatment of peptic ulcer and the prevention of its recurrence]. Gibiński K; Nowak A; Marlicz K; Depczyńska A; Dzieniszewski J; Milewski B; Gabryelewicz A; Kosidło S Pol Tyg Lek; 1984 Nov; 39(47):1547-50. PubMed ID: 6393096 [No Abstract] [Full Text] [Related]
32. Placebos in clinical trials of peptic ulcer. ACG Committee on FDA-Related Matters. Smith JL Am J Gastroenterol; 1989 May; 84(5):469-74. PubMed ID: 2719003 [TBL] [Abstract][Full Text] [Related]
33. [Controlled clinical study of the effectiveness of a new anti-ulcer drug: thiopropamine]. Masoero G Clin Ter; 1979 Aug; 90(3):261-72. PubMed ID: 399873 [No Abstract] [Full Text] [Related]
34. Risk factors in patients with refractory peptic ulcer. Massarrat S Gastroenterology; 1996 Jul; 111(1):267-8. PubMed ID: 8698215 [No Abstract] [Full Text] [Related]
35. [Sucralfate versus placebo in duodenal ulcer. A clinical endoscopic double-blind controlled study]. Elsborg L; Boysen K; Bruusgaard A; Reinicke V Ugeskr Laeger; 1983 May; 145(19):1440-2. PubMed ID: 6349070 [No Abstract] [Full Text] [Related]
36. [Use of gastrocepin in middle-aged and elderly patients with peptic ulcer]. Kapitanenko AM; Shastin IV; Karnaukhov IuN; Merkur'ev ND; Smirnov PA Klin Med (Mosk); 1986 Mar; 64(3):95-6. PubMed ID: 3520141 [No Abstract] [Full Text] [Related]
40. Some problems in modern anti-ulcer drug evaluation: a comparison of four gastric acid suppressors. Gibinski K Curr Med Res Opin; 1981; 7(8):516-9. PubMed ID: 6273068 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]